10.01.2022 - Superhero cells are key to the efficacy, potency, and durability of therapies across the human health spectrumBRANFORD, Conn., Jan. 09, 2022 (GLOBE NEWSWIRE) - IsoPlexis (NASDAQ: ISO), the Superhuman Cell Company, today announced its preliminary . Seite 1
BRANFORD, Conn., Jan. 09, 2022 (GLOBE NEWSWIRE) IsoPlexis (NASDAQ: ISO), the Superhuman Cell Company, today announced its preliminary unaudited revenue for the full year 2021. Total revenue for 2021
/PRNewswire/ IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of Richard Rew as Senior VP, General.